Atrys Health : H1 2023 earnings broadly in line, guidance reiterated
>Organic sales momentum remains strong - H1 2023 group sales reached € 118m (+33% y-o-y vs. +55% in FY 2022) still fuelled by the perimeter effect from Bienzobas (July 2022), Chilerad and Initia (December 2022) which we estimate contributed to 23-25pp to the group’s sales growth in the first half, implying +8-10% organic growth, in line with our estimates. Precision sales grew +80% y-o-y to € 60m driven by Spain (+177%, Bienzobas, Initia) and LatAm (+35%, Chilerad) wh...Atrys Health SA. Atrys Health SA, formerly Europath Biosciences SL, is Spain-based company primarily engaged in the predictive and personalized oncology therapies. It operates under Atrys brand name. Atrys is a clinical and translational research laboratory dedicated to the diagnosis, prognosis and treatment of cancer, including hematologic and solid malignancies. It has four areas of activity: Laboratory, Telemedicine, Radiotherapy, as well as Research and Development (R&D). The Company has its diagnostic laboratories and translational research in Barcelona and Granada, and offices in Madrid, Spain.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.